Skip to main content
. 2009 May 25;6:63. doi: 10.1186/1743-422X-6-63

Figure 6.

Figure 6

Analysis of the HBeAg seroconversion rate at the end of 12 months follow-up between lamivudine and thymosin versus lamivudine groups.